Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.53 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSV | O60911 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804606 | 1.00 | CTSK (0.53) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL13677188 | 1.00 | CTSK (0.53) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL6803573 | 0.92 | CTSK (0.54) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL4455853 | 0.92 | CTSK (0.54) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL13677168 | 0.92 | CTSK (0.54) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL4456315 | 0.92 | CTSS (0.60) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL4449393 | 0.91 | CTSS (0.47) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL4449169 | 0.89 | CTSS (0.51) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL6803369 | 0.89 | CTSK (0.54) | CTSKCTSSCTSVCTSLHPGDS | |
| SCHEMBL6798717 | 0.89 | CTSK (0.57) | CTSKCTSSCTSVCTSLHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | CTSK 45/4885CTSS 21/4885CTSV 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.